GLP-1 infusion increases natriuresis by reducing tubular sodium reabsorption and reduces hyperfiltration in obese subjects.50 Chronic treatment with arGLP-1 in patients with DM2 has shown no effect on measured GFR and effective renal plasma flow in the fasting or postprandial state, however it maintains its natriuretic effect.51 GLP-1 and its agonists induce natriuresis by inhibition of the Na+/H + exchanger type 3 in the proximal tubule, although interactions with the renin, insulin, or glucagon system cannot be excluded5254 because they reduce circulating levels of RAS components51,5355 (Fig
When demand significantly outpaces supply, basic economics suggest prices increase
Keeping up with routine wellness, including flu and COVID vaccinations, is also highly recommended while undergoing any significant medical treatment
KFF public opinion and survey research is a charter member of the Transparency Initiative of the American Association for Public Opinion Research
NF-B: a nuclear factor-B
Recent Mergers & Acquisitions (M & A) 2025-2026: Mar 2026: BioMarin Pharmaceutical agreed to acquire rare disease biotech Amicus Therapeutics for $4.8B, strengthening metabolic & rare disease franchise overlap with diabetes-associated disorders Mar 2026: Sanofi entered $2.2B acquisition deal for Dynavax Technologies to expand vaccine and immunometabolic pipeline supporting diabetes-comorbidity therapeutics Jan 2026: Eli Lilly and Company announced acquisition of Ventyx Biosciences for $1.2B, expanding cardiometabolic and diabetes-related pipeline into immunology-linked therapies 2026 (closed/announced): Merck & Co
